GO:0032212 positive regulation of telomere maintenance via telomerase: Telomere Elongation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032212 describes any process that activates or increases the frequency, rate or extent of telomeric repeat addition by telomerase.
• Telomerase-mediated telomere maintenance supports unlimited cellular proliferation and is a hallmark of most cancers.
• Positive regulators include telomerase holoenzyme components, telomere-binding proteins, and signaling pathways that control TERT expression or recruitment [2,6].
• Dysregulation of this process is linked to hormone-refractory prostate cancer, osteosarcoma, and other malignancies [1,6].
• Alternative lengthening of telomeres (ALT) represents a telomerase-independent mechanism that can bypass the need for positive regulation of telomerase [4,7].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of positive regulators of telomerase-mediated telomere maintenance [1,3,5].
Description
Telomeres are nucleoprotein structures that protect chromosome ends and are maintained by the ribonucleoprotein enzyme telomerase, which adds telomeric repeats to chromosome termini. The Gene Ontology term GO:0032212, positive regulation of telomere maintenance via telomerase, captures any process that activates or increases the frequency, rate or extent of this telomeric repeat addition. This term is distinct from the core telomerase catalytic activity and from negative regulatory processes, focusing specifically on positive control of telomerase-mediated elongation. Researchers study GO:0032212 because telomerase activation is a critical step in cellular immortalization and tumorigenesis, and because its misregulation contributes to cancer and other diseases [2,6]. Understanding the positive regulators of telomerase-mediated telomere maintenance provides mechanistic insight into proliferation, aging, and cancer therapy [2,6]. The term is also relevant to emerging therapeutic strategies that target telomerase or alternative telomere maintenance pathways [1,4].
positive regulation of telomere maintenance via telomerase At A Glance
| GO ID | GO:0032212 |
|---|---|
| GO term | positive regulation of telomere maintenance via telomerase |
| Ontology | biological_process |
| Synonym | activation of telomere maintenance via telomerase; stimulation of telomere maintenance via telomerase; up regulation of telomere maintenance via telomerase activity; up-regulation of telomere maintenance via telomerase activity; upregulation of telomere maintenance via telomerase activity |
| Major function | Increases the frequency, rate or extent of telomeric repeat addition by telomerase |
| Related process | Telomere maintenance via telomerase (GO:0007004); negative regulation of telomere maintenance via telomerase (GO:0032211) |
| Cellular context | Nucleus; telomerase holoenzyme; telomere ends |
| Disease relevance | Cancer, hormone-refractory prostate cancer, osteosarcoma, ALT tumors |
What Is GO:0032212?
GO:0032212 is a biological process term defined as any process that activates or increases the frequency, rate or extent of the addition of telomeric repeats by telomerase. In other words, it encompasses the upstream signals, protein-protein interactions, and post-translational modifications that enhance the ability of telomerase to elongate telomeres. This term does not describe the catalytic addition of nucleotides itself, but rather the positive regulation of that activity.
Why Is positive regulation of telomere maintenance via telomerase Important in Cell Biology?
Positive regulation of telomere maintenance via telomerase is essential for understanding how cells achieve replicative immortality, a hallmark of cancer. Telomerase activation is observed in the majority of human tumors and is a validated target for anticancer therapy, including hormone-refractory prostate cancer. Conversely, insufficient telomerase activity leads to telomere shortening and cellular senescence, implicating this process in aging and degenerative disorders. The term also helps distinguish telomerase-dependent telomere maintenance from alternative lengthening of telomeres (ALT), which operates in a subset of tumors and may respond to different therapeutic strategies [4,7]. Studying positive regulators of telomerase provides mechanistic biomarkers and candidate drug targets [1,6].
• Enables unlimited proliferative capacity in cancer cells by maintaining telomere length.
• Provides a therapeutic target for hormone-refractory prostate cancer and other malignancies.
• Distinguishes telomerase-positive tumors from ALT-positive tumors for treatment selection [4,7].
• Involved in osteosarcoma biology through phosphorylation-mediated telomere maintenance.
• Contributes to the understanding of cellular aging and senescence.
• Guides development of telomerase inhibitors and telomere-targeting drugs.
• Helps interpret genomic instability and replication stress at telomeres.
• Supports CRISPR-based functional genomics of telomere maintenance pathways [1,5].
What Happens During positive regulation of telomere maintenance via telomerase?
Telomerase holoenzyme assembly and recruitment
In simple terms: The cell builds and brings the telomerase enzyme to chromosome ends.
Positive regulation begins with the assembly of the telomerase holoenzyme, which includes the catalytic subunit TERT, the RNA template TERC, and accessory proteins such as dyskerin. Recruitment of telomerase to telomeres is enhanced by interactions with telomere-binding proteins and by post-translational modifications. For example, NPM1 phosphorylation stabilizes POLD3 and promotes telomere maintenance in ALT-positive osteosarcoma, illustrating how phosphorylation events can positively regulate telomere maintenance. In Saccharomyces cerevisiae, the Ess1 prolyl isomerase represses TERRA transcription and promotes telomere replication, indirectly supporting telomerase-mediated maintenance.
TERT expression and activity upregulation
In simple terms: The cell increases the amount or activity of the telomerase enzyme.
Transcriptional upregulation of TERT is a major mechanism of positive regulation. Oncogenic signaling pathways, including MYC and NF-kB, can increase TERT promoter activity. In hormone-refractory prostate cancer, telomerase is considered a new target because its activity supports continued proliferation. Additionally, post-translational modifications such as phosphorylation can enhance TERT catalytic activity or its interaction with TERC. These regulatory events increase the frequency and rate of telomeric repeat addition, directly fulfilling the definition of GO:0032212.
Telomere accessibility and replication stress relief
In simple terms: The cell makes chromosome ends more accessible so telomerase can work.
Telomeres are protected by shelterin components that can inhibit telomerase access. Positive regulation can involve transient displacement of shelterin proteins or resolution of telomeric R-loops. DNA2 and FANCM function in two distinctive pathways to disrupt TERRA R-loops and suppress replication stress at ALT telomeres, a process that can influence telomere maintenance. In telomerase-positive cells, relief of replication stress at telomeres may indirectly support telomerase action. Ess1 in yeast promotes telomere replication by repressing TERRA, highlighting conserved mechanisms that maintain telomere accessibility.
Integration with cell cycle and proliferation signals
In simple terms: The cell links telomere elongation to growth and division signals.
Positive regulation of telomerase is tightly coupled to cell cycle progression and proliferation cues. Telomerase activity is highest in S phase, when telomeres are replicated. Growth factor signaling and oncogenic activation can upregulate telomerase, reinforcing the link between proliferation and telomere maintenance. In cancer, this integration supports continuous division. Therapeutic targeting of telomerase aims to break this link, as explored in hormone-refractory prostate cancer. The interplay between cell cycle regulators and telomerase provides multiple nodes for positive regulation under GO:0032212.
Key Genes Involved in GO:0032212 positive regulation of telomere maintenance via telomerase
The following genes and proteins are experimentally implicated in positive regulation of telomere maintenance via telomerase or in related telomere maintenance pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TERT | Catalytic subunit of telomerase; adds telomeric repeats | Core enzyme; target for cancer therapy [2,6] |
| TERC | RNA template for telomeric repeat synthesis | Essential telomerase component; mutations cause dyskeratosis congenita |
| DKC1 | Dyskerin; stabilizes telomerase RNA | Telomerase holoenzyme assembly; disease mutations |
| NPM1 | Phosphorylation-mediated stabilization of POLD3 | ALT-positive osteosarcoma telomere maintenance |
| POLD3 | DNA polymerase delta subunit; involved in telomere maintenance | Stabilized by NPM1 phosphorylation in osteosarcoma |
| RAD51 | Homologous recombination factor; ALT telomere maintenance | Target of Withaferin-A in ALT cancer cells |
| DNA2 | Helicase/nuclease; resolves TERRA R-loops | Suppresses replication stress at ALT telomeres |
| FANCM | Fanconi anemia protein; disrupts TERRA R-loops | ALT telomere maintenance pathway |
| ESS1 | Prolyl isomerase; represses TERRA transcription | Promotes telomere replication in yeast |
| BEND2 | Fusion gene in pancreatic neuroendocrine tumors | Correlates with poor prognosis; potential telomere link |
| MYC | Transcription factor; activates TERT expression | Oncogenic positive regulator of telomerase |
| NF-kB | Transcription factor; activates TERT expression | Inflammatory signaling and telomerase upregulation |
| Shelterin complex (TRF1, TRF2, POT1, TIN2, TPP1, RAP1) | Protects telomeres; regulates telomerase access | Modulates positive regulation of telomerase |
| TERRA | Telomeric repeat-containing RNA; regulates telomerase | Repressed by Ess1 to promote telomere replication |
| POLD3 | DNA polymerase delta subunit; telomere maintenance | Stabilized by NPM1 phosphorylation |
| FANCM | Fanconi anemia complementation group M | ALT telomere R-loop resolution |
| DNA2 | DNA replication helicase/nuclease | ALT telomere replication stress suppression |
How Is positive regulation of telomere maintenance via telomerase Regulated?
Positive regulation of telomere maintenance via telomerase is controlled at multiple levels. Transcriptional regulation of TERT by oncogenes such as MYC and NF-kB increases telomerase availability. Post-translational modifications, including phosphorylation, can enhance telomerase assembly or recruitment; for example, NPM1 phosphorylation stabilizes POLD3 and promotes telomere maintenance in osteosarcoma. In yeast, the Ess1 prolyl isomerase represses TERRA transcription, thereby promoting telomere replication and indirectly supporting telomerase-mediated maintenance. Additionally, resolution of TERRA R-loops by DNA2 and FANCM suppresses replication stress at ALT telomeres, which can influence telomere maintenance pathways. These regulatory layers ensure that telomerase activity is coupled to cell cycle and proliferation signals.
positive regulation of telomere maintenance via telomerase and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TERT | Hormone-refractory prostate cancer; telomerase activation | CRISPR knockout or point mutation in prostate cancer cell lines |
| NPM1 | ALT-positive osteosarcoma; telomere maintenance | Phospho-mutant knock-in in osteosarcoma cells |
| RAD51 | ALT cancer; DNA repair destabilization | Knockout or overexpression in ALT cell lines |
| DNA2 | ALT telomere replication stress | Knockout in ALT-positive cells |
| BEND2 | Pancreatic neuroendocrine tumors; poor prognosis | Fusion knock-in in pancreatic neuroendocrine cell models |
Cancer and telomerase activation
Most human cancers activate telomerase to maintain telomeres and achieve replicative immortality. Positive regulation of telomere maintenance via telomerase is therefore a hallmark of tumor cells. In hormone-refractory prostate cancer, telomerase is considered a new therapeutic target because its activity supports continued growth. Small-molecule inhibitors and immunotherapeutic approaches targeting telomerase are under investigation. Understanding the positive regulators of telomerase provides opportunities for combination therapies.
Osteosarcoma and ALT-positive tumors
A subset of osteosarcomas uses alternative lengthening of telomeres (ALT), which is telomerase-independent. NPM1 phosphorylation-mediated stabilization of POLD3 promotes telomere maintenance in ALT-positive osteosarcoma, revealing a non-canonical mechanism that can bypass telomerase. ALT tumors are diagnosed by specific markers and may respond to drugs such as Trabectedin. Targeting ALT pathways, including RAD51 destabilization by Withaferin-A, offers selective killing of ALT cancer cells. These findings highlight the importance of distinguishing telomerase-positive from ALT-positive tumors when studying GO:0032212 [4,7].
Pancreatic neuroendocrine tumors and fusion genes
Recurrent BEND2 fusion genes identified by whole transcriptome sequencing in nonfunctional pancreatic neuroendocrine tumors correlate with poor patient prognosis. Although the direct link to telomerase regulation is not established, such fusion genes may alter transcriptional programs that include telomere maintenance pathways. Further research is needed to determine whether BEND2 fusions impact positive regulation of telomere maintenance via telomerase.
From positive regulation of telomere maintenance via telomerase-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene positively regulate telomerase-mediated telomere maintenance? | CRISPR knockout in telomerase-positive cancer cell lines |
| Does a specific phosphorylation site on NPM1 affect telomere maintenance? | Point mutation knock-in of phospho-deficient or phospho-mimetic NPM1 |
| Does overexpression of TERT increase telomere length? | TERT overexpression via lentiviral transduction |
| Does a fusion gene such as BEND2 alter telomere maintenance? | Knock-in of BEND2 fusion in pancreatic neuroendocrine cells |
| Does loss of DNA2 or FANCM affect ALT telomeres? | CRISPR knockout in ALT-positive cell lines |
| Can a drug target RAD51 in ALT cancer? | RAD51 knockout or overexpression with Withaferin-A treatment |
How to Study the positive regulation of telomere maintenance via telomerase Process
| Method | What It Measures | Typical Application |
|---|---|---|
| TRAP assay | Telomerase enzymatic activity | Confirm positive regulation of telomerase |
| TRF analysis | Telomere length | Assess telomere maintenance after genetic perturbation |
| Q-FISH | Telomere length and copy number at single-cell level | Evaluate ALT vs telomerase-positive tumors |
| RNA-seq | TERT and TERRA transcript levels | Identify transcriptional regulators |
| Phosphoproteomics | Post-translational modifications | Discover NPM1 phosphorylation events |
| Whole transcriptome sequencing | Gene fusions and splice variants | Identify BEND2 fusions in pancreatic tumors |
| Immunofluorescence | Telomere foci and R-loops | Study DNA2/FANCM at ALT telomeres |
| CRISPR screening | Loss-of-function phenotypes | Identify positive regulators of telomerase |
Telomere length measurement
Telomere restriction fragment (TRF) analysis and quantitative FISH (Q-FISH) measure telomere length and can assess the outcome of positive regulation of telomerase. These methods are used to determine whether genetic or pharmacological perturbations alter telomere maintenance. In ALT tumors, telomere length is often heterogeneous and can be evaluated by these techniques.
Telomerase activity assays
The telomeric repeat amplification protocol (TRAP) measures telomerase enzymatic activity in cell lysates. This assay is widely used to confirm positive regulation of telomerase in cancer cells and to evaluate telomerase inhibitors. Combining TRAP with CRISPR knockout of candidate regulators can establish causality.
Transcriptomic and proteomic profiling
RNA-seq can quantify TERT and TERRA expression, while proteomics can identify changes in telomerase holoenzyme components and post-translational modifications [1,5]. Whole transcriptome sequencing has identified BEND2 fusions in pancreatic neuroendocrine tumors, illustrating the power of transcriptomics to discover novel regulators. Phosphoproteomics can reveal signaling events such as NPM1 phosphorylation that stabilize POLD3.
Imaging and R-loop detection
Fluorescence microscopy can visualize telomere foci and R-loops using telomeric probes or antibodies against TERRA:DNA hybrids. DNA2 and FANCM function in disrupting TERRA R-loops at ALT telomeres, and imaging can assess their impact on telomere maintenance. Live-cell imaging of telomerase recruitment is also possible with tagged TERT.
How CRISPR Can Be Used to Study GO:0032212 positive regulation of telomere maintenance via telomerase
Knockout
CRISPR knockout of candidate positive regulators, such as TERT, NPM1, or DNA2, can determine whether they are required for telomerase-mediated telomere maintenance [1,2,7]. Knockout cell lines are generated by introducing indels in early exons, followed by validation of protein loss and telomere length measurement. This approach is used to study hormone-refractory prostate cancer and ALT tumors [6,7].
Point Mutation
Point mutations can be introduced to model specific phosphorylation sites or catalytic residues. For example, phospho-deficient or phospho-mimetic mutations in NPM1 can test the role of phosphorylation in stabilizing POLD3 and promoting telomere maintenance. Point mutations in TERT can dissect catalytic and non-catalytic functions. These models are valuable for understanding precise molecular mechanisms.
Knock-in
Knock-in of fusion genes, such as BEND2 fusions identified in pancreatic neuroendocrine tumors, can model their impact on telomere maintenance and prognosis. Knock-in of tagged TERT or TERC allows visualization and biochemical purification of telomerase complexes. This approach is also used to create reporter cell lines for high-throughput screening.
Overexpression
Overexpression of TERT or other positive regulators can increase telomerase activity and telomere length, mimicking cancer-associated activation. Overexpression models are used to test whether a gene is sufficient to enhance telomere maintenance. In ALT cells, overexpression of RAD51 or NPM1 can modulate ALT activity [1,8]. These models complement knockout studies to establish causality.
How EDITGENE Supports positive regulation of telomere maintenance via telomerase Research
Researchers studying positive regulation of telomere maintenance via telomerase-related genes often need to determine whether a candidate gene is causally involved in telomere elongation, whether specific mutations alter its function, or whether its overexpression is sufficient to drive telomere maintenance. EDITGENE provides a comprehensive suite of CRISPR services to address these questions with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of telomere maintenance via telomerase research.
Frequently Asked Questions About positive regulation of telomere maintenance via telomerase
What is GO:0032212?
GO:0032212 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of the addition of telomeric repeats by telomerase.
What genes are involved in positive regulation of telomere maintenance via telomerase?
Key genes include TERT, TERC, DKC1, NPM1, POLD3, RAD51, DNA2, FANCM, and ESS1, among others [1,2,5,7,8].
How is telomerase-mediated telomere maintenance regulated?
It is regulated transcriptionally (e.g., MYC, NF-kB), post-translationally (e.g., NPM1 phosphorylation), and by telomere accessibility factors such as DNA2 and FANCM [1,2,7].
What diseases are associated with positive regulation of telomere maintenance via telomerase?
Cancer, including hormone-refractory prostate cancer and osteosarcoma, as well as ALT-positive tumors and pancreatic neuroendocrine tumors [1,3,4,6].
What is the difference between telomerase-positive and ALT tumors?
Telomerase-positive tumors use telomerase to maintain telomeres, while ALT tumors use homologous recombination; the two can be distinguished by markers and may require different therapies [4,7].
How can CRISPR be used to study telomere maintenance?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in telomere maintenance pathways [1,3,5].
What methods measure telomerase activity?
The TRAP assay measures telomerase enzymatic activity, while TRF and Q-FISH measure telomere length [2,4].
What is the role of NPM1 in telomere maintenance?
NPM1 phosphorylation stabilizes POLD3 and promotes telomere maintenance in ALT-positive osteosarcoma.
What is TERRA and how does it affect telomerase?
TERRA is telomeric repeat-containing RNA; its repression by Ess1 promotes telomere replication, indirectly supporting telomerase-mediated maintenance.
How does EDITGENE support telomere research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study positive regulation of telomere maintenance via telomerase [1,3,5].
Conclusion
GO:0032212, positive regulation of telomere maintenance via telomerase, is a central biological process that governs cellular immortality and cancer progression. Understanding its molecular players, from TERT and TERC to NPM1, POLD3, DNA2, and FANCM, provides mechanistic insights and therapeutic opportunities. CRISPR-based models and advanced omics methods are essential for dissecting this regulation. EDITGENE offers comprehensive services to accelerate discovery in this field.
References
- 1. Zhao R et al.. 2026. NPM1 phosphorylation-mediated telomere maintenance via stabilization of POLD3 in ALT-positive osteosarcoma: unraveling mechanisms and therapeutic opportunities.. Theranostics 16(8):4224-4244 PMID: 41695477
- 2. Holt SE et al.. 1999. Role of telomerase in cellular proliferation and cancer.. J Cell Physiol 180(1):10-8 PMID: 10362013
- 3. Wood-Trageser MA et al.. 2025. Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Nonfunctional Pancreatic Neuroendocrine Tumors Correlate With Poor Patient Prognosis.. Mod Pathol 38(10):100863 PMID: 40784487
- 4. Pompili L et al.. 2017. Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?. J Exp Clin Cancer Res 36(1):189 PMID: 29273061
- 5. Chen J et al.. 2026. The Ess1 prolyl isomerase represses TERRA transcription and promotes telomere replication in Saccharomyces cerevisiae.. Genetics 232(3) PMID: 41557636
- 6. Biroccio A et al.. 2004. Telomerase as a new target for the treatment of hormone-refractory prostate cancer.. Endocr Relat Cancer 11(3):407-21 PMID: 15369445
- 7. Ragupathi A et al.. 2025. DNA2 and FANCM function in two distinctive pathways in disrupting TERRA R-loops and suppressing replication stress at ALT telomeres.. bioRxiv PMID: 40475582
- 8. Yu Y et al.. 2026. Selective killing of ALT-cancer cells by Withaferin-A involves destabilization of Rad51 and disruption of DNA repair.. Cell Death Dis PMID: 42457656
